Comparative Pharmacology
Head-to-head clinical analysis: DIOVAN HCT versus RENESE R.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIOVAN HCT versus RENESE R.
DIOVAN HCT vs RENESE-R
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Valsartan is an angiotensin II receptor blocker (ARB) that selectively blocks the binding of angiotensin II to the AT1 receptor, causing vasodilation and reduced aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride cotransporter in the distal convoluted tubule, increasing excretion of sodium and water.
Thiazide diuretic; inhibits sodium-chloride symporter in distal convoluted tubule, reducing sodium and water reabsorption.
One tablet orally once daily. Available strengths: 80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg, 320 mg/12.5 mg, 320 mg/25 mg. Titrate to blood pressure response; maximum dose 320 mg/25 mg daily.
Initial: 5 mg orally once daily, increased as needed to 10 mg once daily; maximum 10 mg/day.
None Documented
None Documented
Valsartan: 6 hours; hydrochlorothiazide: 6–15 hours (mean 9.6 hours). Clinical context: allows once-daily dosing; half-life prolonged in renal impairment.
Terminal elimination half-life: 13-16 hours; clinical context: supports once-daily dosing
Valsartan: primarily biliary (83%) and renal (13%) as unchanged drug; hydrochlorothiazide: renal (≥95%) as unchanged drug.
Renal: 50% unchanged; fecal: 0%; biliary: 0%
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination